The current price of NOVO-B.CO is DKK 271.25 — it has decreased by 4.89% since the previous close. Data as of Nov 5, 2026.
NOVO-B.CO is up 2.44% over the past week, up 9.91% over the past month and down 9.90% over the past year. The price is below its 200-day moving average of DKK 283.14.
Of the 26 analysts covering Novo Nordisk A/S, 5 rate it a buy, 15 rate it a hold, 5 rate it a sell and 1 rates it a strong sell. The overall consensus is neutral. Analyst ratings are opinions and do not guarantee future performance.
Novo Nordisk A/S has a market capitalization of DKK 1.2T. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Novo Nordisk A/S posted earnings of DKK 5.84 per share against an estimate of DKK 4.79, beating expectations by 21.92%. Upcoming reports are listed in the earnings calendar.
Novo Nordisk A/S reported revenue of DKK 79.85B in its most recent quarter, which has increased by 5.00% compared with the same quarter a year earlier. Analysts had expected DKK 73.65B.
Yes. Novo Nordisk A/S pays dividends semi-annually. The latest payment of DKK 3.75 per share has a payment date of Aug 18, 2026, which corresponds to a dividend yield of 3.97%.
Companies most comparable to Novo Nordisk A/S include Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., Merck & Co., Inc. and Amgen Inc.
In the latest trading session NOVO-B.CO moved between DKK 268.45 and DKK 282.85, a range of 5.31% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Novo Nordisk A/S shows a sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks NOVO-B.CO has traded between DKK 224.25 and DKK 409.95. The current price is 33.83% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.